Insider Transactions in Q1 2021 at Teva Pharmaceutical Industries LTD (TEVA)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2021
|
Mark Sabag EVP, International Markets |
BUY
Exercise of conversion of derivative security
|
Direct |
5,712
+4.88%
|
-
|
|
Feb 14
2021
|
David Matthew Stark Exec. VP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,926
+36.26%
|
-
|
|
Feb 09
2021
|
Richard Daniell Exec. VP, European Commercial |
SELL
Open market or private sale
|
Direct |
68,422
-50.14%
|
$821,064
$12.72 P/Share
|
|
Feb 09
2021
|
Richard Daniell Exec. VP, European Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
55,287
+41.11%
|
-
|
|
Feb 09
2021
|
Richard Daniell Exec. VP, European Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
13,135
+35.47%
|
-
|
|
Feb 09
2021
|
Sven Dethlefs EVP, North America Commercial |
SELL
Open market or private sale
|
Direct |
29,657
-17.57%
|
$355,884
$12.69 P/Share
|
|
Feb 09
2021
|
Sven Dethlefs EVP, North America Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
55,287
+38.3%
|
-
|
|
Feb 09
2021
|
Sven Dethlefs EVP, North America Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
13,135
+28.0%
|
-
|
|
Feb 09
2021
|
Eric Drape Executive VP Global Operations |
SELL
Open market or private sale
|
Direct |
17,979
-17.0%
|
$215,748
$12.72 P/Share
|
|
Feb 09
2021
|
Eric Drape Executive VP Global Operations |
BUY
Grant, award, or other acquisition
|
Direct |
27,643
+33.17%
|
-
|
|
Feb 09
2021
|
Eric Drape Executive VP Global Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
6,567
+18.96%
|
-
|
|
Feb 09
2021
|
Hafrun Fridriksdottir Executive VP, Global R&D |
SELL
Open market or private sale
|
Direct |
29,496
-11.82%
|
$353,952
$12.69 P/Share
|
|
Feb 09
2021
|
Hafrun Fridriksdottir Executive VP, Global R&D |
BUY
Grant, award, or other acquisition
|
Direct |
67,852
+34.38%
|
-
|
|
Feb 09
2021
|
Hafrun Fridriksdottir Executive VP, Global R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
16,120
+20.72%
|
-
|
|
Feb 09
2021
|
Gianfranco Nazzi EVP, International Markets |
SELL
Open market or private sale
|
Direct |
21,635
-13.75%
|
$259,620
$12.72 P/Share
|
|
Feb 09
2021
|
Gianfranco Nazzi EVP, International Markets |
BUY
Grant, award, or other acquisition
|
Direct |
50,260
+37.99%
|
-
|
|
Feb 09
2021
|
Gianfranco Nazzi EVP, International Markets |
BUY
Exercise of conversion of derivative security
|
Direct |
11,941
+27.31%
|
-
|
|
Feb 09
2021
|
Brendan P. O'Grady EVP, North America Commercial |
SELL
Open market or private sale
|
Direct |
20,694
-10.82%
|
$248,328
$12.69 P/Share
|
|
Feb 09
2021
|
Brendan P. O'Grady EVP, North America Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
67,852
+40.71%
|
-
|
|
Feb 09
2021
|
Brendan P. O'Grady EVP, North America Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
16,120
+34.22%
|
-
|
|
Feb 09
2021
|
Mark Sabag EVP, International Markets |
BUY
Grant, award, or other acquisition
|
Direct |
65,339
+38.22%
|
-
|
|
Feb 09
2021
|
Mark Sabag EVP, International Markets |
BUY
Exercise of conversion of derivative security
|
Direct |
15,523
+27.82%
|
-
|
|
Feb 09
2021
|
Kare Schultz President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
226,173
+23.51%
|
-
|
|
Feb 09
2021
|
Kare Schultz President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,867
+5.01%
|
-
|
|
Feb 09
2021
|
David Matthew Stark Exec. VP Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
65,312
-56.51%
|
$783,744
$12.69 P/Share
|
|
Feb 09
2021
|
David Matthew Stark Exec. VP Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,774
+43.59%
|
-
|
|
Feb 09
2021
|
David Matthew Stark Exec. VP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,538
+44.7%
|
-
|